It’s true that GSK’s (LSE: GSK) share price has already risen 28% from its 11 July 12-month low of £13.13.
It’s also true, however, that just because a stock’s risen sharply doesn’t mean that there’s no value left in it. It could simply be that the company’s worth more now than it was before.
In fact, it could be worth even more than the current share price reflects.
In GSK’s case, I think this could well be true.
New cancer drug trial results
On 7 March it said tests now show its Blenrep drug helps extend life in plasma cell cancer patients.
In 2022, it was withdrawn from the US after it failed to demonstrate that it was better than existing treatments.
However, GSK plans to file the results of the new Blenrep tests with the US authorities shortly.
This followed news on 6 February that the US Food and Drug Administration has fast-tracked a review for its Arexvy respiratory syncytial virus vaccine.
If approved, this would be the first vaccine available to help protect those aged 50-59 against the disease.
On 13 February, Citigroup raised GSK stock to a ‘Buy’ recommendation for the first time in seven years.
Analysts there also said they expect peak risk-adjusted Blenrep sales of around £2.5bn.
Still undervalued against
Even before these latest two announcements, GSK looked undervalued compared to its peers.
On the key price-to-earnings (P/E) ratio measurement, it currently trades at just 13.8 against a peer group average of 25.3.
A discounted cash flow analysis shows GSK shares to be around 58% undervalued at their present price of £16.81. Therefore, a fair value would be around £40.02.
This doesn’t necessarily mean that they’ll ever reach that price. But it confirms to me that they still look very good value, even after the recent share price rise.
Core business also looks strong
There are risks, of course, in any business and GSK is no different. Product development is expensive in the pharmaceutical sector, so if one fails then it is a major setback.
Legal action is also common against pharmaceutical firms, with the Zantac litigation against GSK a case in point. However, on 23 June last year, GSK announced that the lawsuits had been settled.
This said, the company’s promising new drugs come on top of already excellent 2023 results, in my view.
Revenue rose 3.4% to £30.3bn from 2022, while net income increased 11% to £4.93bn over the same period.
For 2021-2026, it expects a 7% compound annual growth increase for sales (against the previous 5%). Adjusted operating profit is forecast to grow more than 11% (versus 10% before) on the same basis.
By 2031, GSK now expects to achieve sales of more than £38bn. This is an increase of £5bn over the estimate given in 2021.
Even before news of the new drugs, I thought GSK’s share price was set to soar, as it looked very undervalued against its peers. These new products may mean this happens quicker than I thought.
In either event, I am extremely happy to already have my holding in the stock at a much lower level. But if I did not have this I would absolutely buy the shares right now for the reasons mentioned above.
The post Is GSK’s share price set to soar on a new cancer drug? appeared first on The Motley Fool UK.
5 stocks for trying to build wealth after 50
Inflation recently hit 40-year highs… the ‘cost of living crisis’ rumbles on… the prospect of a new Cold War with Russia and China looms large, while the global economy could be teetering on the brink of recession.
Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.
Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…
We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.
Claim your free copy now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#ffffff”, ‘color’, ‘#FFFFFF’);
})()
More reading
I’m itching to buy these 3 hidden FTSE gems in a Stocks and Shares ISA
Despite being around an 18-month high, GSK’s share price looks cheap to me
Just released: our 3 top income-focused stocks to buy before March [PREMIUM PICKS]
At £16.70, I think this FTSE 100 stock could be 24% undervalued!
2 contrasting FTSE income stocks investors should consider snapping up!
Simon Watkins has positions in GSK. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
